These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22475955)

  • 1. [Post-transfusional iron overload, iron loading anemia].
    Rose C
    Rev Med Interne; 2012 Jun; 33 Suppl 1():S15-8. PubMed ID: 22475955
    [No Abstract]   [Full Text] [Related]  

  • 2. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 5. Current approach to iron chelation in children.
    Aydinok Y; Kattamis A; Viprakasit V
    Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.
    Messa E; Biale L; Castiglione A; Lunghi M; Bonferroni M; Salvi F; Allione B; Ferrero D; Calabrese C; De Gobbi M; Nicoli P; Gioia D; Levis A; Saglio G; Cilloni D
    Leuk Lymphoma; 2017 Nov; 58(11):2752-2754. PubMed ID: 28482720
    [No Abstract]   [Full Text] [Related]  

  • 10. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathogenesis of transfusional iron overload and iron chelation therapy].
    Ozawa K
    Rinsho Ketsueki; 2009 Jul; 50(7):527-31. PubMed ID: 19638719
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation: an update.
    Sheth S
    Curr Opin Hematol; 2014 May; 21(3):179-85. PubMed ID: 24504090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of chronic iron overload.
    Baxter B
    Paediatr Nurs; 2002 Sep; 14(7):14-6. PubMed ID: 12271869
    [No Abstract]   [Full Text] [Related]  

  • 16. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transfusional iron overload in the haemoglobinopathies.
    Thuret I
    C R Biol; 2013 Mar; 336(3):164-72. PubMed ID: 23643400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron overload and chelation.
    Hershko C; Link G; Konijn AM; Ioav Cabantchik Z
    Hematology; 2005; 10 Suppl 1():171-3. PubMed ID: 16188664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron deficiency and overload.
    Beutler E; Hoffbrand AV; Cook JD
    Hematology Am Soc Hematol Educ Program; 2003; ():40-61. PubMed ID: 14633776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.